Affiliation:
1. University of Massachusetts Medical Center, Worcester;
2. Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL;
3. Simmons Cooper Cancer Institute, Southern Illinois University, Springfield;
4. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and
5. Telik, Palo Alto, CA
Abstract
Abstract
Phase 1 testing of ezatiostat, a glutathione S-transferase P1-1 inhibitor, for the treatment of myelodysplastic syndrome was conducted in a multidose-escalation study. Patients received 10 dose levels (200, 400, 1000, 1400, 2000, 2400, 3000, 4000, 5000, and 6000 mg) of ezatiostat tablets in divided doses on days 1 to 7 of a 21-day cycle for a maximum of 8 cycles. The safety and pharmacokinetics of ezatiostat were evaluated. Forty-five patients with low to intermediate-2 International Prognostic Scoring System risk myelodysplastic syndrome were enrolled. No dose-limiting toxicities were observed. The most common grade 1 or 2, respectively, treatment-related adverse events were nonhematologic: nausea (56%, 9%), diarrhea (36%, 7%), vomiting (24%, 7%), abdominal pain (9%, 0%), constipation (4%, 9%), anorexia (3%, 7%), and dyspepsia (3%, 7%). Concentration of the primary active metabolite, TLK236, increased proportionate to ezatiostat dosage. Seventeen hematologic improvement (HI) responses by International Working Group criteria were observed at dose levels of 200 to 6000 mg/day with 11 HI responses at doses of 4000 to 6000 mg/day. HI responses occurred in all lineages including 3 bilineage and 1 complete cytogenetic response. Decreased number of red blood cell and platelet transfusions and in some cases transfusion independence were attained. Extended dose schedules of ezatiostat tablets are under investigation. This study was registered at http://www.clinicaltrials.gov as NCT00280631.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference31 articles.
1. Morphology and classification of myelodysplastic syndromes.;Kouides;Hematol Oncol Clin North Am,1992
2. Chronic myelodysplastic syndrome: Short survival with or without evolution to acute leukaemia.;Weisdorf;Br J Haematol,1983
3. Myelodysplastic syndromes: natural history and features of prognostic importance.;Mufti,1986
4. Classification of the myelodysplastic syndromes.;Bennett,1986
5. International scoring system for evaluating prognosis in myelodysplastic syndromes.;Greenberg;Blood,1997
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献